A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
Saved in:
| Title: | A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). |
|---|---|
| Authors: | Pinter T; Department of Oncoradiology, Petz Aladár Teaching Hospital, Györ, Hungary. Electronic address: pinterbely@gmail.com., Klippel Z; Clinical Development, Amgen Inc, Thousand Oaks, CA., Cesas A; Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania., Croitoru A; Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania., Decaestecker J; Department of Oncology, AZ Delta Hospital, Roeselare, Belgium., Gibbs P; Department of Oncology, The Western Hospital, Footscray, Victoria, Australia., Hotko Y; Uzhgorod Regional Oncology Dispensary, Uzhgorod National University, Uzhgorod, Ukraine., Jassem J; Department of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland., Kurteva G; Clinic of Medical Oncology, Specialized Hospital for Active Treatment in Oncology Sofia, Sofia, Bulgaria., Novotny J; Department of Oncology, Institute of Oncology and Rehabilitation, Nová Ves pod Pleší, Czech Republic., O'Reilly S; Department of Medical Oncology, Ireland Cooperative Oncology Research Group, Dublin, Ireland., Salek T; Department of Clinical Oncology, National Cancer Institute, Bratislava, Slovakia., Reiner M; Global Biostatistical Sciences, Amgen Inc, Thousand Oaks, CA., Morrow PK; Clinical Development, Amgen Inc, Thousand Oaks, CA., Choi MR; Clinical Development, Amgen Inc, Thousand Oaks, CA., Whittaker S; Clinical Development, Amgen Inc, Thousand Oaks, CA., Blanke C; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR. |
| Source: | Clinical colorectal cancer [Clin Colorectal Cancer] 2017 Jun; Vol. 16 (2), pp. 103-114.e3. Date of Electronic Publication: 2016 Sep 07. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101120693 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0674 (Electronic) Linking ISSN: 15330028 NLM ISO Abbreviation: Clin Colorectal Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 28038865 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Pinter+T%22">Pinter T</searchLink>; Department of Oncoradiology, Petz Aladár Teaching Hospital, Györ, Hungary. Electronic address: pinterbely@gmail.com.<br /><searchLink fieldCode="AU" term="%22Klippel+Z%22">Klippel Z</searchLink>; Clinical Development, Amgen Inc, Thousand Oaks, CA.<br /><searchLink fieldCode="AU" term="%22Cesas+A%22">Cesas A</searchLink>; Department of Medical Oncology, Klaipeda University Hospital, Klaipeda, Lithuania.<br /><searchLink fieldCode="AU" term="%22Croitoru+A%22">Croitoru A</searchLink>; Department of Medical Oncology, Fundeni Clinical Institute, Bucharest, Romania.<br /><searchLink fieldCode="AU" term="%22Decaestecker+J%22">Decaestecker J</searchLink>; Department of Oncology, AZ Delta Hospital, Roeselare, Belgium.<br /><searchLink fieldCode="AU" term="%22Gibbs+P%22">Gibbs P</searchLink>; Department of Oncology, The Western Hospital, Footscray, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Hotko+Y%22">Hotko Y</searchLink>; Uzhgorod Regional Oncology Dispensary, Uzhgorod National University, Uzhgorod, Ukraine.<br /><searchLink fieldCode="AU" term="%22Jassem+J%22">Jassem J</searchLink>; Department of Oncology and Radiotherapy, Medical University Gdansk, Gdansk, Poland.<br /><searchLink fieldCode="AU" term="%22Kurteva+G%22">Kurteva G</searchLink>; Clinic of Medical Oncology, Specialized Hospital for Active Treatment in Oncology Sofia, Sofia, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Novotny+J%22">Novotny J</searchLink>; Department of Oncology, Institute of Oncology and Rehabilitation, Nová Ves pod Pleší, Czech Republic.<br /><searchLink fieldCode="AU" term="%22O'Reilly+S%22">O'Reilly S</searchLink>; Department of Medical Oncology, Ireland Cooperative Oncology Research Group, Dublin, Ireland.<br /><searchLink fieldCode="AU" term="%22Salek+T%22">Salek T</searchLink>; Department of Clinical Oncology, National Cancer Institute, Bratislava, Slovakia.<br /><searchLink fieldCode="AU" term="%22Reiner+M%22">Reiner M</searchLink>; Global Biostatistical Sciences, Amgen Inc, Thousand Oaks, CA.<br /><searchLink fieldCode="AU" term="%22Morrow+PK%22">Morrow PK</searchLink>; Clinical Development, Amgen Inc, Thousand Oaks, CA.<br /><searchLink fieldCode="AU" term="%22Choi+MR%22">Choi MR</searchLink>; Clinical Development, Amgen Inc, Thousand Oaks, CA.<br /><searchLink fieldCode="AU" term="%22Whittaker+S%22">Whittaker S</searchLink>; Clinical Development, Amgen Inc, Thousand Oaks, CA.<br /><searchLink fieldCode="AU" term="%22Blanke+C%22">Blanke C</searchLink>; Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Sciences University, Portland, OR. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101120693%22">Clinical colorectal cancer</searchLink> [Clin Colorectal Cancer] 2017 Jun; Vol. 16 (2), pp. 103-114.e3. <i>Date of Electronic Publication: </i>2016 Sep 07. – Name: TypePub Label: Publication Type Group: TypPub Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier%22">Elsevier </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101120693 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1938-0674 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2215330028%22">15330028 </searchLink><i>NLM ISO Abbreviation: </i>Clin Colorectal Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=28038865 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.clcc.2016.08.008 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 103 Titles: – TitleFull: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Pinter T – PersonEntity: Name: NameFull: Klippel Z – PersonEntity: Name: NameFull: Cesas A – PersonEntity: Name: NameFull: Croitoru A – PersonEntity: Name: NameFull: Decaestecker J – PersonEntity: Name: NameFull: Gibbs P – PersonEntity: Name: NameFull: Hotko Y – PersonEntity: Name: NameFull: Jassem J – PersonEntity: Name: NameFull: Kurteva G – PersonEntity: Name: NameFull: Novotny J – PersonEntity: Name: NameFull: O'Reilly S – PersonEntity: Name: NameFull: Salek T – PersonEntity: Name: NameFull: Reiner M – PersonEntity: Name: NameFull: Morrow PK – PersonEntity: Name: NameFull: Choi MR – PersonEntity: Name: NameFull: Whittaker S – PersonEntity: Name: NameFull: Blanke C IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 06 Text: 2017 Jun Type: published Y: 2017 Identifiers: – Type: issn-electronic Value: 1938-0674 Numbering: – Type: volume Value: 16 – Type: issue Value: 2 Titles: – TitleFull: Clinical colorectal cancer Type: main |
| ResultId | 1 |
